A carregar...
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies. Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2003
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2377091/ https://ncbi.nlm.nih.gov/pubmed/12644816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600817 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|